AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) is scheduled to issue its quarterly earnings data before the market opens on Wednesday, November 1st. Analysts expect the company to announce earnings of ($0.07) per share for the quarter.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative return on equity of 4.81% and a negative net margin of 7.58%. The firm had revenue of $158.39 million for the quarter, compared to the consensus estimate of $158.83 million. During the same quarter in the prior year, the business earned $1.45 EPS. The business’s revenue for the quarter was up 24.3% compared to the same quarter last year. On average, analysts expect AMAG Pharmaceuticals to post $-1.5 EPS for the current fiscal year and $-3.07 EPS for the next fiscal year.

AMAG Pharmaceuticals, Inc. (NASDAQ AMAG) opened at 15.55 on Wednesday. The firm’s 50-day moving average price is $18.27 and its 200 day moving average price is $18.90. AMAG Pharmaceuticals, Inc. has a 12-month low of $15.20 and a 12-month high of $36.83. The firm’s market cap is $548.73 million.

TRADEMARK VIOLATION NOTICE: “AMAG Pharmaceuticals, Inc. (AMAG) Scheduled to Post Quarterly Earnings on Wednesday” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/10/25/amag-pharmaceuticals-inc-amag-scheduled-to-post-quarterly-earnings-on-wednesday.html.

AMAG has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a report on Wednesday, October 4th. BidaskClub upgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 6th. Cantor Fitzgerald reiterated a “hold” rating on shares of AMAG Pharmaceuticals in a report on Monday, July 24th. Deutsche Bank AG set a $24.00 price target on shares of AMAG Pharmaceuticals and gave the stock a “hold” rating in a report on Friday, July 7th. Finally, Citigroup Inc. cut their price target on shares of AMAG Pharmaceuticals to $24.00 and set a “hold” rating on the stock in a report on Friday, July 7th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $26.92.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Earnings History for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.